Multiple Sclerosis is an inflammatory disease of the central nervous system in which T cells experience a second phase of activation, which ultimately leads to axonal demyelination and neurological disability. The recent advances in stem cell therapies may serve as potential treatments for neurological disorders. There are broad types of stem cells such as neural, embryonic, mesenchymal and hematopoietic stem cells with unprecedented hope in treating many debilitating diseases. In this paper we will review the substantial literature regarding experimental and clinical use of these stem cells and possible mechanisms in the treatment of MS. These results may pave the road for the utilization of stem cells for the treatment of MS.
INTRODUCTION
Multiple Sclerosis is an inflammatory disease of the central nervous system in which T cells experience a second phase of activation, which ultimately leads to axonal demyelination and neurological disability. 1 MS in most patients is characterized with axonal loss underlying long-term progressive disability. Disease-modifying treatments reduce the progression rate of the disease, but do not stop it. Both drug therapy and neurorehabilitation have shown to ease the burden of some symptoms, though neither influences disease progression. [2] [3] [4] Stem cells are unspecialized cells in the body that have the ability to proliferate or reproduce, and differentiate into other type of body cells with specialized functions. 5, 6 Stem cell therapies may serve as potential treatments for neurodegenerative disease. 6, 7 There are broad types of stem cells such as neural (NSCs), embryonic (ESCs), mesenchymal (MSCs) and hematopoietic stem cells (HSCs) with unprecedented hope in treating many debilitating diseases. In this paper, we will review the substantial literature regarding experimental and clinical use of these stem cells and possible mechanisms in the treatment of MS.
MATERIALS AND METHODS Study Selection
We performed a comprehensive electronic search on the Pub Med and ISI web of science for all studies of Multiple Sclerosis (MS) based on the cell therapy using following terms: "Tissue Therapy", "Neural stem cells", "Mesenchymal stem cell", "hematopoietic or haematopoietic peripheral blood stem cell", "Multiple Sclerosis" and all possible combinations between 1/1/1990 and 31/12/2012. These search terms were confirmed with a MeSH database. Out of 28272 studies, 77 that met our primary criteria of interest were selected (Fig. 1) . Finally, 11 titles and abstracts of articles were screened. 
Inclusion Criteria
Study design: All trial studies were included in the evaluation since these study designs are essential for the systematic review.
Participants: Studies that included tissue therapy and Multiple Sclerosis conditions were included in the evaluation.
Exclusion criteria
The studies that showed not enough data for analysis were excluded after contacting corresponding author twice.
Data Extraction
Two reviewers independently screened all titles and abstracts. Full paper manuscripts of any titles/abstracts that appeared to be relevant were obtained and the relevance of each study was independently assessed by two reviewers according to the inclusion and exclusion criteria. Two authors collected data and reached an agreement on all of the eligible items, including author, journal and year of publication, location of study and selection.
RESULTS AND DISCUSSION
Neural Stem Cells (NSCs) for the Treatment of MS Overall, 8 studies included different models of NSCs applications in MS were selected through the search process (Table 1) . NSCs can be isolated from the adult central nervous system (CNS). The subventricular zone (SVZ) of lateral ventricle wall is a major germinal region that is used for isolation of NSCs. 8, 9 The migratory properties of NSCs are selfrenewing, multipotent and long-distance migrants within the inflamed CNS. [10] [11] [12] [13] [14] [15] These properties make NSCs suitable for cellular therapy in brain. 16 However, there is an increasing evidence that NSCs have neuroprotective and immunomodulatory effects.
17 Although these findings clearly confirmed tremendous potential of NSCs therapy for patients with MS (Table 1) , a lot of work still needs to be done to prove their clinical effectiveness and safety. 
Hematopoietic Stem Cell Transplantation in MS
A total of 48 studies including different models of hematopoietic stem cell (HSC) applications in MS were selected through the search (Table 3) . HSCs are multipotent stem cells that give rise to all the blood cell types from the lymphoid to myeloid lineages. There is increasing use of HSC transplantation over the last years for the treatment of hematological and non-hematological neoplasms and several autoimmune diseases, including MS. 52 In MS, T cells experience a second phase of activation, which ultimately leads to axonal demyelination and neurological disability.
53
Treatment of multiple sclerosis (MS) has 2 aspects: immunomodulatory therapy for the underlying immune disorder and therapies to relieve or modify symptoms. Hence, first-line immunomodulatory therapies for multiple sclerosis (MS) reduce the relapse rate and slow progression of disability, but are not successful for all patients. Some patients cannot tolerate these therapies or have a suboptimal response and therefore require changes in therapeutic management. Early recognition of suboptimal response and prompt intervention are necessary to limit future impairment. 54 Patients with relapse have good response to allogenic or autologous HSC transplantation, as a viable therapeutic option.
55-57
Several studies in animal models of MS and human revealed that HSC transplantation can induce MS remission. [58] [59] [60] However, a few studies present that HSC transplantation has no effect on MS improvement.
Experimental autoimmune encephalomyelitis (EAE)-diseased mice have shown that allogenic HSC transplantation during acute phase of MS lead to full remission. 61, 62 Moreover, autologous HSC transplantation in EAE mice resulted in complete remission. 63, 64 In this regard, Takahashi et al., transduced TREM-2 (an innate immune receptor) in bone marrowderived myeloid precursor cells and intravenously injected to mice with EAE. They observed that TREM-2 transduced myeloid precursors ameliorate clinical symptom of MS in mice with EAE by clearance of nervous tissue debris and degenerated myelin. 65 Resident perivascular macrophage and microglia in central CNS physiologically derived from myeloid progenitors of hematopoietic cells not only during development, but also in life span. [66] [67] [68] Moreover, it has been presented that some hematopoietic cells are recruited to sites of neurological damage to become functional perivascular macrophage and microglia like dells.
69, 70 Although macrophages play harmful or beneficial roles in CNS injury, they are able to remove the cellular debris in acute phase of injury. [71] [72] [73] Juan et al., evaluated clinical and neurological outcomes after autologous HSC transplantation in 22 patients with progressive MS. They showed that it can improve or stabilize neurological manifestations in most patients with progressive MS, following failure of conventional therapy. 74 Proposed mechanism for improvement of MS symptoms by autologous HSC transplantation is immunity system alteration. 75 Fassas et al., reported the outcomes of 15 patients with progressive MS and a median EDSS of 6.0 by HSC transplantation after conditioning. During 6 months of follow-up, no death and worsening of neurological symptoms were observed and EDSS was improved in 7 of 15 patients.
56
In the study conducted by Saiz et al., 5 patients with progressive MS and median EDSS of 6.5 underwent HSCT after BCNU, cyclophosphamide and ATG conditioning. Based on MRI findings, 4 patients showed improvement, whereas neurological symptoms worsened in the fifth one. 76 Large series of MS patients including 85 cases were evaluated by the European Group for Blood and Marrow Transplantation (EBMT) Working Party on Autoimmune Diseases. The study included patients with secondary progressive MS (70%) and primary progressive MS (26%). The median EDSS of patients was 6.5 (ranging from 4.5 to 8.5), so the patients were subjected to HSCT after conditioning. At a median follow-up of 16 months, the chance of progression -free survival was 74% at 3 years. Five patients died of treatment-related complications including infection and cardiac failure. 77 Patients with both hematological neoplasms and autoimmune diseases inconsistently respond to HSC transplantation. 78 HSCT indeed leads to extensive renewal of the T-cell repertoire provided crucial evidence to document that autologous HSCT goes beyond a profound and long-lasting immunosuppression, which can be achieved by conventional treatment in MS (132) Lutterotti Auto-HSCT treatment strategies based on the level of disability, namely "early," "conventional," and "salvage/late" transplantation, appears to be feasible to improve treatment outcomes ( 
Human
The estimated probability of MS progression, defined as an increase in EDSS score by > or = 1.0 sustained for at least 180 days, was 5% after one year, 14% after two years, 22% after three years, 38% after five years, 57% after 10 years, and >80% after 20 years of observation (158 
Significant transplant-related morbidity and mortality have been observed. This is primarily due to complications related to either the stage of the disease at transplant or due to infections. The number of deaths related to cardiac toxicity is low (162) Blanco Autologous HSCT appears feasible in MS; it does not aggravate disability and seems to offer a clinical benefit. However, these observations need confirmation and long-term outcomes will show if benefits counterbalance toxicity and cost(56)
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Embryonic Stem Cell Application in MS Treatment
Only three studies were reviewed in detail on the use of Embryonic stem cells (ESCs) in MS. ESCs are pluripotent stem cells that derived from the inner cell mass of an early stage embryo called blastocyst. [82] [83] [84] They are able to develop into any type of cell in the body. The actual limitation in preparation of sufficient human oligodendrocyte precursor cells obligate research in getting tissuespecific progenitor cells from human embryonic stem cells (hESCs). Many studies have tried to differentiate mouse embryonic stem cells (mESCs) into oligodendrocyte with myelogenic properties. [85] [86] [87] Moreover, studies have revealed that hESCs can be directed into neural cells. 84, [88] [89] [90] Interestingly, recent studies discovered several systems such as small molecules and specific transcription factors that control ESC fate to produce neurons [91] [92] [93] [94] and oligodendrocytes. 95, 96 hESC-derived oligodendrocytes are capable of remyelination. 95, 97 However, there are always risk of tumorigenesisin neural cells derived from ESCs, limiting the potentialities of science and therapy in such studies.
55 hESC-based therapies can give rise to specific specialty cells such as, dermatomes from undifferentiated ESCs or incompletely differentiated neural cells. 98, 99 Aharonowiz et al., transplanted hESC-derived neural progenitors into the mice with EAE. 100 They observed that clinical symptoms of EAE remarkably reduced after transplantation. Histological evaluation revealed that transplanted neural progenitors migrate to the mice brain, especially in the host white matter. However, remyelination and production of mature oligodendrocytes were not clearly observed.
Besides, they concluded that the therapeutic effect of neural progenitor's transplantation was mediated by an immunosuppressive neuroprotective mechanism. Further studies are required to define the efficacy of ESC-derived neural cell therapy in MS patients.
CONCLUSION
Nowadays, Stem cell therapy in axonal demyelination and neurological disability (Specially MS) had been accelerated growth in animal model as well as human patient clinical treatment. A new way that promotes this procedure is tissue engineering which uses synthesis of natural polymer that simulates extra cellular matrix for better response of body to grafted cells. 
